Trial Profile
Remicade safety line (Crohn's disease)
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 10 May 2022
Price :
$35
*
At a glance
- Drugs Infliximab (Primary)
- Indications Crohn's disease
- Focus Therapeutic Use
- Sponsors Merck & Co; Merck Sharp & Dohme; Schering-Plough
- 31 Jan 2012 Actual patient number changed from 149 to 148 as reported by ClinicalTrials.gov.
- 28 Jan 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 20 Jan 2010 Planned end date changed from 1 Dec 2009 to 1 Dec 2010 as reported by ClinicalTrials.gov.